Background
==========

Colorectal adenocarcinoma is the second leading cause of cancer-related death in the world. The stage of the disease is related to the survival of the patient \[[@b1-medscimonit-23-1146]\], and in early phases surgery is the main modality of treatment. The main aim of modern medical chemistry is to synthesize small molecules via drug designing, especially by targeting the tumor cell. Clinical trials reported that the substitution pattern to the different heterocycles also influences carcinogenesis. Some of the characteristic properties of the malignant phenotype of colorectal cancer are mediated by overexpression and/or activation of receptor tyrosine kinases, pointing to these molecules as attractive anticancer treatment targets. One of these approaches is the inhibition of epidermal growth factor (EGF) receptor (EGFR) either by EGFR tyrosine kinase inhibition or antibody-induced receptor blockade. Inhibition of EGFR signaling significantly inhibits tumor growth in numerous preclinical models, including colon cancer models \[[@b2-medscimonit-23-1146]--[@b5-medscimonit-23-1146]\].

Targeted drug design for anticancer studies proves protein kinases as a feasible target for drug development \[[@b6-medscimonit-23-1146],[@b7-medscimonit-23-1146]\]. It is next most important target after G-protein linked receptor. The role of certain tyrosin kinases, particularly epidermal GFR, plays an important role in regulating cell proliferation. Overexpression of EGFR has been reported in 25--82% of colorectal cancers. Some new studies report protein overexpression in 35--49% of total cases \[[@b8-medscimonit-23-1146]--[@b12-medscimonit-23-1146]\]. The wide range of EFFR expression in colorectal cancer is reported in many studies, and EGFR expression as a prognostic indicator may be related to the methodology used to detect EGFR \[[@b13-medscimonit-23-1146]--[@b15-medscimonit-23-1146]\]. Therefore, the design of inhibitors that target EFFR-TK is a better approach to new drug development ([Figure 1](#f1-medscimonit-23-1146){ref-type="fig"}). Lapatinib, Imatinib, and Erlotinib are widely used as EGFR-TK inhibitors for the treatment of cancer \[[@b16-medscimonit-23-1146],[@b17-medscimonit-23-1146]\].

Benzothiazole is a versatile nucleus and widely reported to have various biological activities, such as antitumor \[[@b18-medscimonit-23-1146]\], antimicrobial \[[@b19-medscimonit-23-1146]\], antitubercular \[[@b20-medscimonit-23-1146]\]*,* antioxidant \[[@b21-medscimonit-23-1146]\], and antidepressant \[[@b22-medscimonit-23-1146]\] activities. Moreover, thiazole and its derivatives are reported to have various pharmacological activities, such as antitubercular \[[@b23-medscimonit-23-1146]\], antibacterial \[[@b24-medscimonit-23-1146]\], antidepressant \[[@b25-medscimonit-23-1146]\], and antitumor \[[@b26-medscimonit-23-1146]\] activities. Benzothiazole derivatives bearing thiazole moiety were reported to have antiproliferative activity against colon cancer cell lines HCT-116, HT29, HCT-15, and caco-2 \[[@b27-medscimonit-23-1146]\].

Rational and design
-------------------

It is well known that quinazoline is a versatile moiety for the inhibition of an extensive range of tyrosine kinases, and EGFR is the most studied receptor of tyrosine kinases \[[@b28-medscimonit-23-1146]\]. So, in the present work we tried to design a new series of compounds using molecular modeling studies which contain a benzothiazole core as the EGFR-TK inhibitor. The designed molecules are the structural analogs of 4-anilino-quinazoline of 'tinibs' (Erlotinib, Lapatinib, and Gefinitib) ([Figure 2](#f2-medscimonit-23-1146){ref-type="fig"}) with varied chemical properties. Isosteric replacement of the quinazoline ring with benzothiazole may mimic the ATP competitive binding regions of EGFR-TK \[[@b26-medscimonit-23-1146]--[@b28-medscimonit-23-1146]\]. We were guided by information obtained in our literature search and by the fact that benzothiazole acts in the catalytic domain (EGFR-TK) for ATP binding, showing interaction with the adenine ring with N^1^ and N^6^ through the interaction of hydrophilic and hydrophobic regions and channels ([Figure 2](#f2-medscimonit-23-1146){ref-type="fig"}) \[[@b26-medscimonit-23-1146]\].

It is well known that overexpression of the RTK signaling pathway is mostly associated with occurrence of cancer. Therefore, deactivation of the tyrosine kinase signaling pathway may be a better target for the treatment of cancer. Based on these facts, molecular modeling studies were used to ascertain the interaction of designed moieties with active site of EGFR-TK. For this study, lapatinib was used as a reference compound. We use similarity-based virtual screening because it is a simple and widely used method for ligand-based virtual screening of chemical databases, where bio-isosteric compounds are used \[[@b26-medscimonit-23-1146]\].

Material and Methods
====================

Some new benzothiazole thiazole derivatives were designed. The structures were docked using Accelyres Drug Discovery Studio 3.5 \[[@b29-medscimonit-23-1146]\]. The structure of the enzyme EGFR-TK was obtained from the Protein Data Bank \[[@b30-medscimonit-23-1146]\] (PDB code: 1XKK: [Figure 3](#f3-medscimonit-23-1146){ref-type="fig"}) and was used for docking. The enzyme exists in tetrameric form in the crystal associated with water molecules, which were not considered in docking as they are not found in the ligand zone of the crystal structure. The crystal structure was cleaned by deleting the ligand and cofactors, followed by adding hydrogen atoms to the protein. The ligand structure was imported to the new window with proper names and the program was run to prepare the ligand. Finally, the input ligands were selected (Molecules: All) on the protein molecular window and docked for 1XKK. The setup for side-chain flexibility by selection of the all-visible option and the setting for the other selected chain during the docking and other parameters were kept in default. The binding energy and electrostatic interaction energy were calculated (docking analysis [Table 1](#t1-medscimonit-23-1146){ref-type="table"}).

Ligand preparation
------------------

The ligand structures were drawn in 2D using Marvin Sketch (ChemAxon), then the 2D structures were converted into 3D by using the same software. Optimization of structure and energy minimization were done to confirm the stable ligands.

Protein preparation
-------------------

The protein was prepared by using the standard protocol. In the first step, missing residue was added, followed by removal of water molecules, and atom names were standardized. All the related energies (e.g., TE, PE, and VDW energy) were noted before and after minimization.

Synthetic studies
-----------------

Based on the result of dockings, the compounds showing good binding affinity with the receptor were selected for the synthetic studies.

[Scheme 1](#f10-medscimonit-23-1146){ref-type="fig"}: Synthesis of 1- (6-chloro-1,3-benzothiazol-2-yl)-3-substituted thiourea
-----------------------------------------------------------------------------------------------------------------------------

In the mixture of (1) (0.02 mol) in EtOH (50 mL), substituted isothiocyanate (0.02 mol) was put in and the resultant solution was heated under reflux for 10 h. The resultant reaction mixture was then distilled under vacuum for removal of solvent, if any. The solid product was obtained and washed with Et~2~O and recrystallized using rectified spirit to obtain a pale yellow product (2.a--2.c).

**2.a:** *1-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,5-difluorophenyl) thiourea:* mp 210--212° (CH~3~OH); R~f~ 0.56 (ACN: Me 1:1); FTIR (KBr) cm^−1^: 3215, 3229 (amine), 1310 (C=S stretch) cm^−1^; ^1^H NMR (CDCl~3~): δ, 6.66--7.72 (m, 8H, Ar-H), 7.56 (s, 1H, Amide), 9.98 (s, 1H, NH), 10.79 (s, 1H, NH-Ar); FABMS (m/z, 100%): 355 (\[M+1\], 100%). C (47.21%) H (2.22%) N (11.81%), calculated for C~14~H~8~ClF~2~N~3~S~2~ C (47.27%) H (2.27%) N (11.81%).

**2.b:** *1-(6-chloro-1,3-benzothiazol-2-yl)-3-(3,5-dichlorophenyl) thiourea:* mp 201--204° (CH~3~OH); R~f~ 0.59 (ACN: Me 1:1); FTIR (KBr) cm^−1^: 3210, 3227 (NH), 735 (C-Cl stretching)1312 (C=S stretching) cm^−1^; ^1^H NMR (CDCl~3~): δ 6.55--7.23 (m, 7H, Ar-H), 7.50 (s, 1H, CO-NH), 0.40 (s, 1H, NH), 10.92 (s, 1H, NH-Ar); FABMS (m/z, 100%): 388 (\[M+2\], 100%). C(43.26%) H(2.02%) N(10.81%), calculated for C~14~H~8~Cl~32~N~3~S~2~ C(43.26%) H(2.07%) N(10.81%).

**2.c:** *1-(6-chloro-1,3-benzothiazol-2-yl)-3-(4-nitrophenyl)thiourea:* mp 218--220° (CH~3~OH); R~f~ 0.7 (CAN: Me 1:1); FTIR (KBr) cm^−1^: 3210, 3229 (NH), 735 (C-Cl stretching)1320 (C=S stretching) cm^−1^; 1510 (NO~2~-Ar Stretching) ^1^HNMR (CDCl~3~): δ 6.23--7.49 (m, 7H, Ar-H), 7.74 (s, 1H, CO-NH), 0.39 (s, 1H, NH), 10.92 (s, 1H, NH-Ar); FABMS (m/z, 100%): 364 (\[M+2\], 100%). C(46.09%) H (2.42%) N (15.36%), calculated for C~14~H~9~ClN~4~O~2~S~2~ C(46.09%) H(2.47%) N(15.36%).

[Scheme 2](#f11-medscimonit-23-1146){ref-type="fig"}: Synthesis of 6-chloro-N-\[3,4-disubstituted-1,3-thiazol-2(3H)-ylidene\]-1,3-benzothiazol-2-amine
------------------------------------------------------------------------------------------------------------------------------------------------------

A mixture of the (2.a--2.c) (0.01 mole) with different substituted phenacyl bromide (0.01 mole) and sodium acetate (1.3 g, 0.1 mole) in EtOH (30 ml) was heated under reflux for 7 h. The reaction mixture was stabilized for 1 h and then water was added to develop cloudiness. The resultant mixture was kept overnight for complete reaction. The solid product obtained was filtered, washed with water, and recrystallized from spirit to obtain the final product.

As discuss earlier, the compounds showing good binding affinity towards the receptor were used for the synthetic studies.

**BT1:** *3-{2-\[(6-chloro-1,3-benzothiazol-2-yl)amino\]-3-(2,4-difluorophenyl)-2,3-dihydro-1,3-thiazol-4-yl}phenol:* Rf: 0.60 (ACN: Me 1:1), MP 370--373°C FTIR, 3133.44 (Ar C-H), 1640 (C=N),1550 (C-C),1280 (CN), 3540(N-H), ^1^HNMR (CDCl~3~), 4.1 (s, 1H,NH), 6.4--7.9 (m,7H, Ar-H), 6.9--7.9 (m,3H,2-benzothiazole),5.35 (s,Ar-OH), FABMS (m/z 100%) 473; anal. Found C(55.25%) H(2.97%), N(8.85%) for C~22~H~14~ClF~2~N~3~OS~2~, calculated C(55.75%) H(2.98%) N(8.87%).

**BT4:** *N-\[4-(3-bromophenyl)-3-(2,4-difluorophenyl)-2,3-dihydro-1,3-thiazol-2-yl\]-6-chloro-1,3-benzothiazol-2-amine:* Rf: 0.56 (ACN: Me 1:1), MP 375--380°C IR, 3136.44 (Ar C-H), 1670.88(C=N),1558.38, C-Br 790, (C-C), 1320.18 (CN),3534.31(N-H),^1^HNMR (CDCl~3~), 4.08 (s, 1H, NH), 6.50--7.30 (m,7H, Ar-H), 6.9--7.9 (m,3H,2-benzothiazole), FABMS (m/z 100%) 536; anal. Found C(49.11%) H(2.43%), N(7.79%) for calculated C~22~H~13~BrClF~2~N~3~S~2~ C(49.22%) H(2.44%) N(7.83%)

**BT8:** *6-chloro-N-\[4-(3-chlorophenyl)-3-(2,4-dichlorophenyl)-2,3-dihydro-1,3-thiazol-2-yl\]-1,3-benzothiazol-2-amine:* Rf: 0.54 (ACN: Methanol 1:1), MP 315--320°C IR, 3144.44 (Ar C-H), 1641.12(C=N), 1558.38, C-Cl 693, (C-C),1340.18 (CN),3520.31(N-H), ^1^HNMR (CDCl~3~), 4.11 (m, 2H, NH), 6.56--7.48 (m,7H, Aryl-H), 7.5--8.2(m,3H,2-benzothiazole), FABMS (m/z 100%) 525; anal. Found C(50.30%) H(2.49%), N(8.00%) for calculated C~22~H~13~Cl~4~N~3~S~2~ C(50.30%) H(2.49%) N(8.00%).

**BT16:** *6-chloro-N-\[3-(4-nitrophenyl)-4-phenyl- 2,3-dihydro- 1,3-thiazol- 2-yl\]-1,3-benzothiazol-2-amine:* Rf: 0.74 (ACN: Methanol 1:1), MP 279--281°C IR, 3140.44 (Ar C-H), 1621.12 (C=N),1558.38, C-Cl 693, (C-C),1340.18 (CN),3550.31(N-H), ^1^HNMR (CDCl~3~), 4.21 (m, 2H, NH), 6.46--7.71 (m,8H, Aryl- H), 7.5--8.2(m,3H,2-benzothiazole), FABMS (m/z 100%) 466; anal. Found C(56.59%) H(3.25%), N(12.00%) for calculated C~22~H~15~ClN4O~2~S~2~ C(56.59%) H(3.24%) N(12.00%).

**BT17:** *6-chloro-N-\[4-(3-chlorophenyl)-3-(4-nitrophenyl)-2,3-dihydro-1,3-thiazol-2-yl\]-1,3-benzothiazol-2-amine:* Rf: 0.66 (ACN: Methanol 1:1), MP 300--310°C IR, 3122.44 (Ar C-H), 1621.12(C=N), 1566.38, C-Cl 693, (C-C),1340.18 (CN),3540.31(N-H), ^1^HNMR (CDCl~3~), 4.10 (m, 2H, NH), 6.46--6.99 (m,8H, Ar-H), 7.3--7.9 (m,3H,2-benzothiazole), FABMS (m/z 100%) 501; anal. Found C(52.70%) H(2.81%), N(11.17%) For Calculated C~22~H~14~Cl~2~N~4~O~2~S~2~ C(52.70%) H(2.81%) N(11.17%).

**BT18:** *3-{2-\[(6-chloro-1,3-benzothiazol-2-yl)amino\]-3-(4-nitrophenyl)-2,3-dihydro-1,3-thiazol-4-yl}phenol:* Rf: 0.6 (ACN: Methanol 1:1), MP 340--342°C IR, 3120.44 (Ar C-H), 1611.88 (C=N),1512.38 (C-C),1333.18 (CN),3533.31(N-H),1500--1600 (Ar-NO~2~), ^1^HNMR (CDCl~3~), 4.11 (s, 1H,NH), 6.4--7.11 (m,7H, Ar-H), 6.9--8.33(m,3H,2-benzothiazole),FABMS (m/z 100%) 482.90; anal. Found C(54.70%) H(3.13%), N(11.60%) For C~22~H~15~ClN~4~O~3~S~2~ Calculated C(54.71%) H(3.13%) N(11.60%).

Anticancer activity
-------------------

The synthesized compounds were evaluated for their anticancer activity at the National Institute of Cancer (NCI).

Toxicity assays
---------------

The toxicity assay was performed by the standard protocol of the manufacturer. Toxi-light assay method was used to measure the toxicity of the compounds.

Results
=======

Analysis of docking
-------------------

The designed compounds were docked at the assigned site of the protein. The results of docking and the binding energy of every compound with the receptor are listed in [Table 1](#t1-medscimonit-23-1146){ref-type="table"}. The ligands with good binding scores showed good interactions with the receptor. The ATP binding pocket is hydrophobic by nature, and the hydrophobic interaction play a vital role in affinity towards EGFR-TK binding. At least 2 hydrogen bonds of ligand and receptor are necessary for small molecules to act as EGFR inhibitors ([Figures 4](#f4-medscimonit-23-1146){ref-type="fig"}[](#f5-medscimonit-23-1146){ref-type="fig"}[](#f6-medscimonit-23-1146){ref-type="fig"}[](#f7-medscimonit-23-1146){ref-type="fig"}[](#f8-medscimonit-23-1146){ref-type="fig"}--[9](#f9-medscimonit-23-1146){ref-type="fig"}).

Synthetic studies
-----------------

The moieties were synthesized according to the above-mentioned procedure. The synthesized compounds were characterized by using FTIR, ^1^HMNR, Mass, and C, H, N, Analysis. Because the electron density is the crucial factor in the reactivity, the substitutions were performed at N~2~ as it is more electron-rich than N1 \[[@b31-medscimonit-23-1146]--[@b33-medscimonit-23-1146]\].

Antiproliferative activity
--------------------------

The anticancer evaluation of the synthesized compounds was performed at the Developmental Therapeutic Program (*[www.dtp.nci.nih.gov](www.dtp.nci.nih.gov)*) of the US National Cancer Institute (NCI), using the standard protocol for anticancer evaluation. The compounds were evaluated for their action against non-small cell lung cancer and colon cancer (HCT116, HCT-15, and HT29) cell lines at NCI using standard protocol and the procedure is contained in their website. The compounds were firstly assessed for 1-dose testing. If they were found to be active at 1-dose testing, they were further evaluated for 5-dose testing. Inhibition of growth 50% (GI50) values were calculated for each cell line ([Table 2](#t2-medscimonit-23-1146){ref-type="table"}).

Discussion
==========

The compounds (BT1, BT4, BT8, BT17, and BT18) were found to have substantial activity in 1-dose testing and were further evaluated for 5-dose testing using the SRB (sulforhodamine B) protein assay. The compound B16 showed moderate activity, so it was not selected for further testing. The dose-dependent parameters for 5-dose testing were calculated for 5-dose antiproliferative activity, and dose-response parameters (GI~50~,(TGI) and LC~50~) were evaluated for synthesized compounds against all cell lines. Furthermore, (MG_MID) was deliberated for every parameter, which gives an average activity parameter over all cell lines for tested compounds. The results of the present study indicate that the synthesized compounds exhibit good antiproliferative activity against colon cancer cell lines (HCT116, HCT15, and HT29) compared with the reference. The synthesized compounds showed notable selectivity against the tested cancer cell lines. The tested compounds (BT1, BT4, BT8, BT17, and BT18) showed good antiproliferative activity against the tested cancer cell lines with selectivity pattern. They showed better activity against selected colon cancer cell lines with log GI~50~ ranging from −7.20 to −4.80. ([Table 2](#t2-medscimonit-23-1146){ref-type="table"}). The compounds showed a good selectivity pattern, so their activity against cancer cell lines was confirmed ([Tables 3](#t3-medscimonit-23-1146){ref-type="table"}, [4](#t4-medscimonit-23-1146){ref-type="table"}).

For SAR studies, common substituent pattern was followed. The different substituent in compounds BT1 to BT18 reveals that substitution on positions 3 and 4 of the thiazole ring plays an important role in the biological activity. Furthermore, the presence of electron withdrawing groups BT1, BT4, BT8, BT17, and BT18 showed better antiproliferative activity. It was previously reported that electron-withdrawing/donating groups mostly affect the biological activity because it significantly affects the lipophilicity of the compound, which is a key factor in crossing the barriers of the cell membrane \[[@b32-medscimonit-23-1146]--[@b33-medscimonit-23-1146]\].

On the basis of these results, the SAR study revealed that:

-   For better anticancer activity, position 3 of thiazole may be substituted by the electron-withdrawing group for good activity, which might impart its lipophilicity, strengthening their hydrophobic interactions with the receptor.

-   Hydroxyl group introduction may increase the activity, as it may be involved in hydrogen-binding with the receptor.

-   Position 2 of thiazole does not affect the activity.

Conclusions
===========

The synthesized compounds exhibited good anti-tumor activity against different colon cancer cell lines. The compound BT17 shows potent activity against all the colon cell lines with the GIC50 values in the molecular range. It can be concluded from the present study that hydrophobic group substitution is the primary structural requirement for fitting into the active pocket of the receptor, with 2 hydrogen bond acceptors and 1 hydrogen bond donor. The results of the present study can be used for the discovery of some new antiproliferative agents. Moreover, these compounds may be further tested for their activity against other cancer types.

**Source of support:** Departmental sources

![ATP binding site showing hydrophobic region, sugar pocket, adenine region, and hydrophobic region.](medscimonit-23-1146-g001){#f1-medscimonit-23-1146}

![Reported anticancer compounds and designed benzothiazole derivatives showing bioisosteric replacement.](medscimonit-23-1146-g002){#f2-medscimonit-23-1146}

![The crystal structure of EGFR kinase domain (pdb code *1XKK*) in complex with lapatinib.](medscimonit-23-1146-g003){#f3-medscimonit-23-1146}

![Docking interaction of Compound BT-1 with *1XKK*. Dashed line represents H bonds.](medscimonit-23-1146-g004){#f4-medscimonit-23-1146}

![Docking interaction of compound BT-16 with *1XKK.* Dashed line represents H bonds.](medscimonit-23-1146-g006){#f6-medscimonit-23-1146}

![Docking interaction of compound BT-4 with *1XKK.* Dashed line represents H bonds.](medscimonit-23-1146-g005){#f5-medscimonit-23-1146}

![Docking interaction of compound BT-17 with *1XKK.* Dashed line represents H bonds.](medscimonit-23-1146-g007){#f7-medscimonit-23-1146}

![Docking interaction of compound BT-18 with *1XKK.* Dashed line represents H bonds.](medscimonit-23-1146-g008){#f8-medscimonit-23-1146}

![Docking interaction of Lepatinib with *1XKK*. D dashed line represents H bonds.](medscimonit-23-1146-g009){#f9-medscimonit-23-1146}

![Synthesis of Compounds 2.a--2.c](medscimonit-23-1146-s001){#f10-medscimonit-23-1146}

![Synthesis of compounds BT1-BT19.](medscimonit-23-1146-s002){#f11-medscimonit-23-1146}

###### 

Docking analysis of compounds.

  Sr. No.   Compound    Amino acid                     Bond             Binding energy   Inhibitory constant (uM)   Inter molecular energy   Electrostatic energy
  --------- ----------- ------------------------------ ---------------- ---------------- -------------------------- ------------------------ ----------------------
  1         LEPATINIB   LYS806, ILE938, Gly--512       HO, HH, NH       −10.26           125.89                     −10.54                   −3.5
  **2**     **BT1**     **LYS806; SER912; ILE938**     **HH; HH; HN**   −**6.64**        **13.55**                  −**7.83**                −**0.32**
  3         BT2         LYS806; LYS806                 HN; HN           −5.94            44.42                      −7.13                    −0.22
  4         BT3         LYS806                         HH               −5.31            128.27                     −6.5                     0.09
  **5**     **BT4**     **LYS806; Leu--305**           **HH; OH**       −**6.12**        **39.98**                  −**7.19**                −**0.24**
  6         BT5         LYS806                         --               −5.35            119.49                     −6.54                    −0.08
  7         BT6         LYS806                         --               −5.72            63.69                      −6.92                    −0.05
  8         BT7         LYS806                         HN               −4.88            265.76                     −6.07                    −0.09
  **9**     **BT8**     **LYS806, SER912; Glu--514**   **HH, NH, HH**   −**6.23**        **27.02**                  −**7.43**                −**0.02**
  10        BT9         ARG803                         HO               −5.87            49.59                      −7.07                    −0.18
  11        BT10        LYS806; LYS806                 HO; HN           −5.62            76.57                      −7.11                    −0.25
  12        BT11        LYS806                         --               −5.65            72.3                       −7.14                    −0.15
  13        BT12        LYS806                         HO               −5.66            70.71                      −6.86                    −0.1
  14        BT13        --                             --               −5.38            113.31                     −6.58                    0.03
  15        BT14        --                             --               −5.47            98.3                       −6.66                    0.01
  16        BT15        LYS806                         HN               −5.43            104.74                     −6.62                    −0.09
  **17**    **BT16**    **LYS806, ASP807**             **HO, HN**       −**6.36**        **21.54**                  −**7.86**                −**1.36**
  **18**    **BT17**    **LYS806, ASN808**             **HO, NH**       −**6.41**        **20.16**                  −**7.9**                 −**1.25**
  **19**    **BT18**    **ASP807; ASN808**             **HN; HN**       −**6.36**        **21.86**                  −**7.85**                **0.11**
  20        BT19        LYS806                         HO               −5.94            44.1                       −7.73                    −0.86

The bolded compounds show good binding and were used for synthetic studies.

###### 

Results for anticancer evaluation at concentration 10^−5^ M.

  Compound No.   Subpanel tumor cell lines colon cancer   Active (selected for 5-dose 60 cell lines assay)           
  -------------- ---------------------------------------- -------------------------------------------------- ------- ----------
  BT1            12.36                                    10.3                                               2.9     Active
  BT4            11.41                                    9.43                                               3.0     Active
  BT8            2.46                                     11.32                                              4.5     Active
  BT16           11.46                                    0.43                                               0.23    Inactive
  BT17           15.67                                    4.23                                               6.7     Active
  BT18           7.12                                     11.10                                              14.47   Active
  Lapatinib      22.31                                    27.23                                              36.12   --

###### 

Dose-dependent assay for anticancer evaluation.

  Compound No.   N[a](#tfn2-medscimonit-23-1146){ref-type="table-fn"}   LogGI~50~   Log TGI          Log LC~50~                                                       
  -------------- ------------------------------------------------------ ----------- ---------------- ------------ ---- ---------------- ------- ---- ---------------- -------
  BT1            3                                                      3           −4.64 to −6.49   −5.07        56   −4.0 to −4.83    −4.4    19   −4.0 to −4.36    −4.06
  BT4            3                                                      3           −4.64 to −6.52   −5.33        37   −4.0 to 5.08     −4.36   09   −4.0 to −4.28    −4.02
  BT8            3                                                      3           −4.0 to −4.84    −4.45        08   −4.0 to −4.24    −4.02   00   −4.0 to −4.02    −4.0
  BT17           3                                                      3           −4.42 to −5.02   −4.71        25   −4.0 to −4.32    −4.07   03   −4.0 to −4.08    −4.0
  BT18           3                                                      3           −3.92 to −6.93   −4.90        49   −3.92 to −6.01   −4.07   49   −3.92 to −4.75   −4.29

N -- no. of human cancer cell lines tested at the II^nd^ stage assay;

N1, N2, N3 -- no. of sensitive cell lines, against which the compound possessed considerable growth inhibition as per the standard parameter (logGI~50~, logTGI, and log LC50 ≥4.00) (GI~50~ (50% of net cell growth inhibition at molar concentration of the compound.) TGI (Total inhibition at molar concentration of the compound) and LC~50~ (50% of net cell death at molar concentration of the compound).

###### 

The sensitivity pattern of synthesized compounds.

  Compd. No.   Cancer type    Most sensitive cell line   Log GI~50~   LOG TGI   Log LC~50~
  ------------ -------------- -------------------------- ------------ --------- ------------
  BT1          Colon cancer   HCT-116                    −5.31        −4.64     \>−4.00
  HC-29        −5.19          −4.49                      \>−4.00                
  BT-4         Colon cancer   HCT116                     −5.59        −4.70     \>−4.00
  HCT15        −5.71          −5.28                      −4.27                  
  HC29         −6.52          −4.42                      \>−4.00                
  BT-8         Colon cancer   HCT116                     −6.01        \>−4.00   \>−4.00
  HCT15        −5.59          −4.70                      \>−4.00                
  HC29         −5.71          −5.28                      −4.27                  
  BT-16        Colon cancer   HCT116                     −5.59        −4.70     \>−4.00
  HCT15        −5.71          −5.28                      −4.27                  
  HC29         −5.58          −5.07                      −4.06                  
  BT-17        Colon cancer   HCT116                     −5.59        −4.70     \>−4.00
  HCT15        −5.71          −5.28                      −4.27                  
  HC29         −5.58          −5.07                      −4.06                  
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